so many institutions in emerging fields completely neuter their ability to make impact by refusing to distance themselves from the crazy people that were there at the start. high variance is useful early on, but many fields like longevity still suffer for decades for it
-
-
A very well known researcher in the space told me during a call that the field is full of bs, so fits.
-
And I didn't even ask 'Hey how robust is the field', it was more a random remark uttered in a 'obviously, everyone knows this is fucked up, nothing new here'
- Show replies
New conversation -
-
-
Agreed. Additionally: i think biotech has a massive visual communication problem. Bright vitamin gummies and mystic charlatans are more visually engaging than other content out there. Tough to get people engaged & working (unlike rockets/manufacturing/etc), need to solve this.
-
Emerging markets (Longevity, psychedelics, crypto, etc) need to focus on media first. In concept, good marketing, PR, and changing the perception of a field is very do-able and the the ROI of opening up these markets would be enormous.
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.